Situmace
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharma Dynamics (Pty) Ltd | Situmace | 000 mg 50/1, 50/850 mg | 560725, 560726 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Situmace 50/850 MG EACH TABLET CONTAINS SITAGLIPTIN PHOSPHATE MONOHYDRATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 850,0 mg | 50/850 mg | 56072556/21.2/0725 | Registered | Not determined | None |
| Situmace 50/1 000 MG EACH TABLET CONTAINS SITAGLIPTIN PHOSPHATE MONOHYDRATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 1000,0 mg | 000 mg 50/1 | 56072656/21.2/0726 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.